Analyst Downgrades Immunic After Lack of Details Drive Uncertainty
Analyst Downgrades Immunic After Lack of Details Drive Uncertainty
在缺乏細節導致不確定性之後，分析師下調了Immunic的評級
- SVB Leerink has downgraded Immunic Inc (NASDAQ:IMUX) to Market Perform from Outperform following disappointing initial data from the highly anticipated Phase 1b proof-of-concept study for IMU-935 in patients with moderate-to-severe psoriasis. The analyst lowered the price target to $5 from $9.
- "While we appreciate that this is an interim readout in which many study aspects are still blinded, we believe the limited data disclosure creates significant uncertainty around the potential path forward for IMU-935," SVB writes.
- IMUX expects to report detailed data from this study in 1Q23, which they believe may clarify why the treatment failed to separate from the placebo.
- The analyst continues to see fundamental value for lead program vidofludimus calcium (IMU-838) in RRMS.
- SVB notes the costs and extended timelines to pivotal data for this program (topline data from the first Phase 3 trial expected by YE25) and believes investors are likely to approach IMUX's early pipeline as a "show-me story" given the recent clinical setbacks in UC and PsO.
- Price Action: IMUX shares are down 76.96% at $2.12 on the last check Friday.
- SVB Leerink 已降級 Immunc Inc 納斯達克股票代碼：IMUX）從跑贏大盤跌至市場表現，此前備受期待的針對中度至重度牛皮癬患者 IMU-935 的1b期概念驗證研究的初步數據令人失望。分析師將目標價從9美元下調至5美元。
- SVB 寫道：“儘管我們意識到這是一箇中期讀數，其中許多研究方面仍然視而不見，但我們認爲，有限的數據披露給 IMU-935 的潛在前進方向帶來了巨大的不確定性。”
- IMUX預計將在23年第一季度報告這項研究的詳細數據，他們認爲這可能會澄清治療未能與安慰劑分離的原因。
- 分析師繼續看到RRMS中主要項目vidofludimus鈣（IMU-838）的基本價值。
- SVB注意到該項目的成本和關鍵數據的時間延長（預計將在YE25之前完成的第一項3期試驗的關鍵數據），並認爲，鑑於加州大學和PSO最近在臨床上遇到了挫折，投資者可能會將IMUX的早期產品線視爲 “給我看故事”。
- 價格走勢： 在週五的最後一張支票中，IMUX股價下跌了76.96％，至2.12美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。